France Rejects Advice To Delay Second Dose Of Pfizer Vaccine
Health Minister Says Move Not Justified By The Evidence
The French government has decided not to extend the recommended interval between the two doses of the Pfizer/BioNTech coronavirus vaccine.
You may also be interested in...
Coronavirus Notebook: EFPIA Attacks EU’s Vaccine Export Authorization Scheme, EMA Starts Rolling Review Of REGN-COV2 Antibody Combo
Médecins Sans Frontières has urged Johnson & Johnson to prioritize vaccine supplies to COVAX, the EMA has clarified the dosing interval for Pfizer/BioNTech’s Comirnaty, and the UK has ordered more vaccine from Valneva.
France's health technology assessment body says that delaying by six weeks the second dose of the two mRNA vaccines approved for use against COVID-19 would allow at least 700,000 more people to receive their jab in the first month.
The pharmaceutical industry and other stakeholders have taken part in the launch event for a new initiative intended to tackle issues that have been amplified by the COVID-19 pandemic, such as supply chain resilience and medicine shortages. The project has drawn a mixed response from industry bodies.